# A Study of YL201 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05434234/  
OnCo record `nct05434234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of YL201 and Atezolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.

## Summary

A Study of YL201 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05434234 by MediLink Therapeutics (Suzhou) Co., Ltd., with 312 participants planned, started 2022-05-25 and due to reach its primary completion in 2027-04-06. Interventions recorded: YL201 and YL201 and atezolizumab.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05434234
- Phase: 1/2
- Setting: A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
- Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
- Enrolled: 312

## Sources

- ClinicalTrials.gov NCT05434234: https://clinicaltrials.gov/study/NCT05434234

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [YL201](https://onco.cc/drugs/yl201/)

---
JSON: https://onco.cc/api/v1/entities/nct05434234.json